169 related articles for article (PubMed ID: 11359635)
1. Specific immunotherapy.
Larché M
Br Med Bull; 2000; 56(4):1019-36. PubMed ID: 11359635
[TBL] [Abstract][Full Text] [Related]
2. Clinical experience with recombinant molecules for allergy vaccination.
Cromwell O; Niederberger V; Horak F; Fiebig H
Curr Top Microbiol Immunol; 2011; 352():27-42. PubMed ID: 21562972
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients.
Rossi RE; Monasterolo G
Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445
[TBL] [Abstract][Full Text] [Related]
4. Prevention of allergen-specific IgE production and suppression of an established Th2-type response by immunization with DNA encoding hypoallergenic allergen derivatives of Bet v 1, the major birch-pollen allergen.
Hochreiter R; Stepanoska T; Ferreira F; Valenta R; Vrtala S; Thalhamer J; Hartl A
Eur J Immunol; 2003 Jun; 33(6):1667-76. PubMed ID: 12778485
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of allergen-specific immunotherapy.
Akdis CA; Blaser K
Allergy; 2000 Jun; 55(6):522-30. PubMed ID: 10858982
[No Abstract] [Full Text] [Related]
6. Next generation immunotherapy for tree pollen allergies.
Su Y; Romeu-Bonilla E; Heiland T
Hum Vaccin Immunother; 2017 Oct; 13(10):2402-2415. PubMed ID: 28853984
[TBL] [Abstract][Full Text] [Related]
7. Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies.
Möbs C; Ipsen H; Mayer L; Slotosch C; Petersen A; Würtzen PA; Hertl M; Pfützner W
J Allergy Clin Immunol; 2012 Nov; 130(5):1108-1116.e6. PubMed ID: 23021882
[TBL] [Abstract][Full Text] [Related]
8. Allergy vaccines--new approaches to an old concept.
Wheeler AW; Woroniecki SR
Expert Opin Biol Ther; 2004 Sep; 4(9):1473-81. PubMed ID: 15335314
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy (desensitization) in allergic disease.
Norman PS
Annu Rev Med; 1975; 26():337-44. PubMed ID: 1096771
[No Abstract] [Full Text] [Related]
10. Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: A randomized controlled trial.
Chaker AM; Shamji MH; Dumitru FA; Calderon MA; Scadding GW; Makatsori M; Jones I; He QA; Subramanian KK; Arm JP; Durham SR; Schmidt-Weber CB
J Allergy Clin Immunol; 2016 Feb; 137(2):452-461.e9. PubMed ID: 26531865
[TBL] [Abstract][Full Text] [Related]
11. Recombinant allergen-based monitoring of antibody responses during injection grass pollen immunotherapy and after 5 years of discontinuation.
Gadermaier E; Staikuniene J; Scheiblhofer S; Thalhamer J; Kundi M; Westritschnig K; Swoboda I; Flicker S; Valenta R
Allergy; 2011 Sep; 66(9):1174-82. PubMed ID: 21480924
[TBL] [Abstract][Full Text] [Related]
12. Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study.
Klimek L; Schendzielorz P; Pinol R; Pfaar O
Clin Exp Allergy; 2012 Jun; 42(6):936-45. PubMed ID: 22909165
[TBL] [Abstract][Full Text] [Related]
13. Birch pollen immunotherapy leads to differential induction of regulatory T cells and delayed helper T cell immune deviation.
Möbs C; Slotosch C; Löffler H; Jakob T; Hertl M; Pfützner W
J Immunol; 2010 Feb; 184(4):2194-203. PubMed ID: 20048125
[TBL] [Abstract][Full Text] [Related]
14. Allergen-related approaches to immunotherapy.
Rolland JM; Gardner LM; O'Hehir RE
Pharmacol Ther; 2009 Mar; 121(3):273-84. PubMed ID: 19111571
[TBL] [Abstract][Full Text] [Related]
15. The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis.
Keskin O; Tuncer A; Adalioglu G; Sekerel BE; Saçkesen C; Kalayci O
Pediatr Allergy Immunol; 2006 Sep; 17(6):396-407. PubMed ID: 16925684
[TBL] [Abstract][Full Text] [Related]
16. [Applicable strategies for the mucosal immune system in the regulation of allergic diseases].
Kurashima Y; Kunisawa J; Kiyono H
Arerugi; 2008 Feb; 57(2):87-94. PubMed ID: 18349582
[No Abstract] [Full Text] [Related]
17. Adequate clinical trials of immunotherapy.
Aas K
Allergy; 1982 Jan; 37(1):1-14. PubMed ID: 6753624
[No Abstract] [Full Text] [Related]
18. Allergen extracts for immunotherapy: to mix or not to mix?
Nony E; Martelet A; Jain K; Moingeon P
Expert Rev Clin Pharmacol; 2016; 9(3):401-8. PubMed ID: 26652799
[TBL] [Abstract][Full Text] [Related]
19. Oral allergy syndrome in patients with airborne pollen allergy treated with specific immunotherapy.
Czarnecka-Operacz M; Jenerowicz D; Silny W
Acta Dermatovenerol Croat; 2008; 16(1):19-24. PubMed ID: 18358104
[TBL] [Abstract][Full Text] [Related]
20. A molecular diagnostic algorithm to guide pollen immunotherapy in southern Europe: towards component-resolved management of allergic diseases.
Douladiris N; Savvatianos S; Roumpedaki I; Skevaki C; Mitsias D; Papadopoulos NG
Int Arch Allergy Immunol; 2013; 162(2):163-72. PubMed ID: 23921568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
